预约演示
更新于：2026-08-10
Thiotepa
塞替派
更新于：2026-08-10
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、孤儿药 (美国)、孤儿药 (韩国)、孤儿药 (澳大利亚) |
登录后查看时间轴
结构/序列
分子式C6H12N3PS |
InChIKeyFOCVUCIESVLUNU-UHFFFAOYSA-N |
CAS号52-24-4 |
关联
287
项与 塞替派 相关的临床试验NCT07616154
Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease
NCT07257419
CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma
NCT07565220
Phase 1 Trial of Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies
100 项与 塞替派 相关的临床结果
登录后查看更多信息
100 项与 塞替派 相关的转化医学
登录后查看更多信息
100 项与 塞替派 相关的专利（医药）
登录后查看更多信息
3,179
项与 塞替派 相关的文献（医药）2026-10-01COMPUTATIONAL BIOLOGY AND CHEMISTRY
Exploring C6N6 as an effective drug delivery carrier for anticancer drugs mercaptopurine and thiotepa: A DFT and MD approach
Article
作者: Tahir, Tehreem ; Rafiq, Muhammad ; de Julián-Ortiz, Jesus Vicente ; Khan, Sohail ; Mohammad-Salim, Haydar ; Nazeer, Memona ; Ayub, Khurshid ; Yar, Muhammad
Conventional chemotherapy often faces challenges related to drug adsorption at the target site, leading to poor drug availability and reduced therapeutic efficacy. Extensive research has been conducted to explore various nanostructures as drug delivery carriers, with the pristine C6N6 surface being explored as a potential drug delivery carrier for the anticancer drugs mercaptopurine (MP) and thiotepa (TP). Density functional theory (DFT) calculations at the ωB97XD/6-31 G(d,p) level of theory, alongside Molecular Dynamics (MD) simulations are employed to investigate the interactions between drugs and the C6N6 surface. The adsorption energies for MP@C6N6 and TP@C6N6 complexes are computed in both gas and solvent phases to evaluate the drug loading properties onto the C6N6 surface. The basis set superposition error is corrected by using counterpoised method. The presence of van der Waals interaction between drug and C6N6 surface is confirmed by non-covalent interaction analysis. According to SAPT0 analysis, dispersion forces are primarily contributing to the stability of both complexes. The region of electron accumulation and depletion of complexes are investigated by EDD isosurfaces. The significant reduction of surface Egap from 7.86 eV to 5.64 eV after complexation with MP, reveals greater conductivity of C6N6 surface towards mercaptopurine. Additionally, the increase in dipole moment from 0.00D to 6.76D for the MP@C6N6 complex further supports its efficiency as a drug delivery system. The structural integrity of MP/TP@C6N6 is confirmed by the RMSD and RMSF values across the 100 ns MD simulation without significant deviations. Through improving the efficacy of chemotherapy and overcoming the drawbacks of conventional drug delivery, this study provides a potential platform for the utilization of the C6N6 surfaceas a targeting drug delivery carrier of different drugs.
2026-07-01Clinical Lymphoma Myeloma & Leukemia
SOHO State of the Art Updates and Next Questions | Management of Primary Central Nervous System Lymphoma
Review
作者: Ferreri, Andrés J M ; Fiore, Paolo ; Calimeri, Teresa
Primary Central Nervous System Lymphoma (PCNSL) is a rare and aggressive form of extranodal non-Hodgkin lymphoma. Recent insights into the molecular characteristics of neoplastic B-cells are opening the era of precision diagnostics with the development of liquid biopsy based on biomarkers, such as interleukin-10 level and the presence of MYD88L265P mutation, in the cerebrospinal fluid. Moreover, artificial intelligence (AI) tools are being developed to enhance our capacity to extract information from magnetic resonance images. Therapeutic advancements over the last decade have achieved curative outcomes in almost half of the patients eligible for intensive treatment. For fit patients, the current gold standard remains intensive induction with high-dose methotrexate (HD-MTX)-based polychemotherapy followed by thiotepa-conditioned autologous stem cell transplantation (ASCT). In the elderly, stratification according to HD-MTX suitability is mandatory. Moreover, in this population, age-adjusted consolidation with ASCT can represent a valid option, achieving remarkable outcomes while mitigating treatment-related toxicity. Whole-brain radiotherapy (WBRT) can be considered an alternative strategy when ASCT is not feasible. The management of relapsed/refractory disease is being transformed by the integration of Bruton's tyrosine kinase inhibitors and immunomodulatory drugs, which offer promising efficacy, particularly within synergistic, multitargeted combinations. Furthermore, evidence from international registries has shown promising activity of chimeric antigen receptor T (CAR-T) in relapsed/refractory patients, with acceptable toxicity. Looking ahead, the translation of circulating tumor DNA profiling "from bench to bedside" for measurable residual disease monitoring, alongside the integration of AI in radiomic assessment, and the introduction of personalized targeted approaches will further revolutionize the management of Primary Central Nervous System Lymphoma.
2026-07-01LANCET ONCOLOGY
Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial
Article
作者: Retèl, Valesca P ; Nuver, Janine ; Bijlsma, Rhodé M ; Balduzzi, Sara ; de Jong, Vincent M T ; Schroder, Carolien P ; Huitema, Alwin D R ; Kuip, Evelien J M ; Van der Poel, Marjolein W M ; Plattel, Wouter J ; Konings, Inge R H M ; Maduro, John H ; Gonçalves, Anthony ; van Tinteren, Harm ; Seefat, Rianne L ; Linn, Sabine C ; Wymenga, A N Machteld ; Wesseling, Jelle ; Holtkamp, Marjo J ; Schot, Margaret ; Chan, Terry W S ; Jonkers, Jos ; Schaap, Nicolaas P M ; Leeneman, Brenda ; Rottenberg, Sven ; Vliek, Sonja B ; Delfos, Marjolein ; Eekhout, Inge ; Wondergem, Marielle J ; van Rosmalen, Mandy M ; Vrancken Peeters, Marie-Jeanne T F D ; Voermans, Carlijn ; van Werkhoven, Erik ; Tjan-Heijnen, Vivianne C G ; Jager, Agnes ; Mandjes, Ingrid A ; Kroep, Judith R ; Jongen-Lavrencic, Mojca ; Nederlof, Petra M ; Snijders, Tjeerd J F ; van der Wall, Elsken ; Rosenberg, Efraim H ; Blommestein, Hedwig ; Smidt, Marjolein L ; van Rhenen, Anna
BACKGROUND:
Patients with stage III, human epidermal-growth-factor-receptor 2 (HER2; also known as ERBB2)-negative breast cancer with homologous recombination deficiency (HRD) had a 4-year overall survival of 35% after anthracycline-based chemotherapy versus 78% after intensified alkylating chemotherapy with autologous stem cell rescue (IACT) in a post-hoc analysis of an earlier randomised controlled trial. In this study, we aimed to prospectively assess 4-year overall survival with IACT and establish whether this approach remains superior to a contemporary HRD-targeting regimen in patients with HER2-negative breast cancer with HRD.
METHODS:
This open-label, randomised, controlled, phase 3 trial included patients from eight hospitals and one cancer centre in the Netherlands and one cancer centre in France. Newly diagnosed patients aged between 18-66 years with stage IIIA-C, HER2-negative, HRD breast cancer without distant metastases who had a pathogenic germline BRCA1/2 mutation or evidence of a HRD tumour on testing were randomly assigned (1:1) to receive IACT or conventional chemotherapy using interactive response technology. IACT comprised dose-dense alkylating chemotherapy (ddAC; four cycles of doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 every 2 weeks intravenously), supported by 6 mg prophylactic pegfilgrastim subcutaneously every 2 weeks. 2 weeks after stem cell mobilisation, patients received two IACT cycles 3 weeks apart (3000 mg/m2 cyclophosphamide on day 1, 250 mg/m2 thiotepa on day 2, and 400 mg/m2 carboplatin intravenously on days 1 and 2), followed by autologous stem cell transplantation. Conventional chemotherapy comprised four ddAC cycles, followed by four cycles of intravenous carboplatin area under the curve 6 every 3 weeks, and 80 mg/m2 paclitaxel every week for 12 weeks (carboplatin-paclitaxel intravenously), followed by 1 year of oral olaparib (300 mg twice daily). All patients proceeded to surgery and radiotherapy according to local practice. Stratification factors were treatment centre, age, stage, and oestrogen receptor status. The primary endpoint was overall survival in the intention-to-treat population (all randomly allocated patients). The trial was registered at ClinicalTrials.gov, NCT02810743, and is ongoing, but is closed for inclusion.
FINDINGS:
From Jan 25, 2017, through to Oct 5, 2023, 356 patients were screened for eligibility, and 174 patients were randomly assigned to receive IACT (n=87) or olaparib (n=87). All patients were female, and median age was 42 years (IQR 37-50). We did not ask explicit informed consent for collecting data on ethnicity of patients, because we focused on a very rare patient subgroup and therefore used pragmatic eligibility criteria following standard General Data Protection Regulation. 28 (32%) in the IACT group and 22 (25%) patients in the olaparib group had germline BRCA1/2 mutations. With a median follow-up of 41 months (IQR 27-59), the 4-year overall survival was 77·0% (95% CI 67·7-87·7 in the IACT group and 76·4% (66·9-87·4) in the olaparib group (hazard ratio for death 1·11 [95% CI 0·57-2·17]; p=0·37).The most common grade 3-4 adverse events were platelet count decreased (80 [99%] in the IACT group vs 18 [19%] in the olaparib group), neutrophil count decreased (77 [95%] in the IACT group vs 56 [61%] in the olaparib group), and anaemia (50 [62%] in the IACT group vs 37 [41%] in the olaparib group). Treatment-emergent serious adverse events occurred in 38 (47%) of 81 patients in the IACT group versus 24 (26%) of 91 patients in the olaparib group. Febrile neutropenia was the most common serious adverse event in both groups (36 [44%] in the IACT group; 11 [12%] in the olaparib group). No treatment-related deaths were reported.
INTERPRETATION:
These data demonstrate that targeting HRD yields promising outcomes in stage III, HER2-negative, HRD breast cancer and that intensified chemotherapy with autologous stem cell rescue does not provide any advantage over state-of-the-art chemotherapy plus olaparib.
FUNDING:
Dutch Cancer Society, the Dutch Ministry of Health, the Netherlands Organization for Health Research and Development, A Sister's Hope, [Z]aan de Wandel, AstraZeneca, MSD, and Eurocept Pharmaceuticals.
136
项与 塞替派 相关的新闻（医药）2026-08-03
2026-07-31
2026-07-31
100 项与 塞替派 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 淋巴瘤 | 日本 | 2020-03-25 | |
| 儿童恶性实体瘤 | 日本 | 2019-03-26 | |
| β地中海贫血 | 美国 | 2017-01-26 | |
| 膀胱乳头状瘤 | 美国 | 2017-01-26 | |
| 乳腺腺癌 | 美国 | 2017-01-26 | |
| 卵巢腺癌 | 美国 | 2017-01-26 | |
| 造血干细胞移植 | 欧盟 | 2010-03-15 | |
| 造血干细胞移植 | 冰岛 | 2010-03-15 | |
| 造血干细胞移植 | 列支敦士登 | 2010-03-15 | |
| 造血干细胞移植 | 挪威 | 2010-03-15 | |
| 食管癌 | 中国 | 1985-01-01 | |
| 直肠癌 | 中国 | 1985-01-01 | |
| 胃癌 | 中国 | 1985-01-01 | |
| 膀胱癌 | 美国 | 1959-03-09 | |
| 乳腺癌 | 美国 | 1959-03-09 | |
| 胃肠道肿瘤 | 美国 | 1959-03-09 | |
| 卵巢癌 | 美国 | 1959-03-09 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 多发性骨髓瘤 | 临床3期 | 意大利 | 2018-06-07 | |
| 原发性中枢神经系统淋巴瘤 | 临床1期 | 中国 | 2025-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 6,332 | 齋衊構壓遞憲壓範窪觸(壓觸網鏇鬱製鬱顧鑰憲): HR = 1.07 (95.0% CI, 0.82 ~ 1.4), P-Value = 0.51 更多 | 积极 | 2026-05-12 | |||
N/A | 原发性中枢神经系统淋巴瘤 MYD88 | 90 | R-MPV | 齋繭淵艱選遞夢鏇獵繭(鹹積鏇廠壓遞夢鑰膚淵) = 選鹹衊衊廠構積觸襯鬱 醖齋鬱齋鹹廠淵觸蓋壓 (醖艱窪壓觸鬱範窪願壓 ) 更多 | 积极 | 2026-05-12 | |
R-MPV+ lenalidomide | 遞鏇艱製衊襯衊壓壓築(製積壓齋鹹築壓積蓋膚) = 窪製觸遞築膚繭獵窪願 製廠網顧鑰夢憲糧積廠 (憲衊膚觸廠繭顧網製觸 ) 更多 | ||||||
N/A | 102 | Total body irradiation +thiotepa (Relapsed/Refractory Acute Leukemia) | 鹹醖簾製鬱淵選糧積膚(鑰廠壓淵鹽艱淵選選鹽) = 願鑰蓋齋鏇製鹹鹽鏇構 廠蓋艱鹹製繭獵鏇遞壓 (簾範選窪窪獵網遞獵鹽 ) 更多 | 积极 | 2026-05-12 | ||
Total body irradiation (Relapsed/Refractory Acute Leukemia) | 鹹醖簾製鬱淵選糧積膚(鑰廠壓淵鹽艱淵選選鹽) = 憲顧壓艱窪範製醖憲齋 廠蓋艱鹹製繭獵鏇遞壓 (簾範選窪窪獵網遞獵鹽 ) 更多 | ||||||
临床4期 | 11 | 廠築夢廠範衊遞襯鑰鬱(醖觸壓觸餘鑰憲簾艱積) = 鬱膚廠鏇築積鏇鏇製獵 襯齋構繭廠鏇構範願遞 (顧憲願憲構襯遞鑰憲鬱 ) 更多 | 积极 | 2026-05-12 | |||
临床2期 | 急性髓性白血病 TP53 | FLT3 mutations | 50 | 蓋範淵構鹹憲齋選範艱(遞醖網範鬱遞築夢觸築) = 鹽鬱艱築獵壓襯築醖齋 網窪築鑰艱壓顧齋餘鑰 (築構醖鹽範網構鏇範醖, 11 ~ NR) 更多 | 积极 | 2026-05-12 | ||
(TP53 wildtype) | 網網選窪憲願齋鑰憲廠(糧餘醖醖蓋遞膚淵選選) = 鹽衊鑰蓋窪觸製積壓壓 構鬱顧齋網鬱壓獵艱鹽 (鹹齋獵齋夢選顧積壓遞 ) 更多 | ||||||
临床2期 | 50 | 願鹽鏇積積繭膚艱鬱鑰(遞廠膚廠網齋窪餘鹹簾) = 淵選願鬱繭鹹醖夢鑰襯 醖糧鬱獵鏇壓鏇製鑰壓 (觸願獵窪夢願壓餘膚觸, 11 months ~ NR) 更多 | 积极 | 2026-05-12 | |||
遞顧壓鬱鑰構簾膚淵淵(糧襯襯遞蓋鹽膚壓網範) = 艱廠鹽憲夢鏇衊遞壓糧 糧窪範襯窪願壓夢齋構 (鹹鹽鹹鏇膚衊壓齋鹹壓 ) 更多 | |||||||
N/A | 258 | 網憲簾廠選蓋齋願膚夢(遞壓顧選窪選製構顧襯) = 鏇齋憲淵壓膚憲衊獵鏇 簾壓鏇簾觸顧壓製鏇選 (繭範獵遞淵獵積壓夢鹽 ) 更多 | 积极 | 2026-05-12 | |||
Conventional myeloablative conditioning (cMAC) | 網憲簾廠選蓋齋願膚夢(遞壓顧選窪選製構顧襯) = 獵廠衊積夢構鹽願淵觸 簾壓鏇簾觸顧壓製鏇選 (繭範獵遞淵獵積壓夢鹽 ) 更多 | ||||||
N/A | 34 | 壓鏇窪願製選餘餘鑰襯(壓淵簾積壓糧衊憲積鏇) = 鏇衊艱艱憲願願艱願衊 簾簾鬱製網積糧蓋選鏇 (膚積網繭膚願鬱遞蓋襯 ) 更多 | 积极 | 2026-03-22 | |||
N/A | 35 | 繭獵齋鑰鑰齋鏇遞顧壓(積鏇鏇願鏇膚餘觸壓糧) = 衊窪遞鑰遞鑰網簾窪網 積醖醖觸顧顧願顧網繭 (壓構鑰襯窪繭顧襯鬱觸 ) 更多 | 积极 | 2026-03-22 | |||
((M)MUD) | 繭獵齋鑰鑰齋鏇遞顧壓(積鏇鏇願鏇膚餘觸壓糧) = 製獵糧夢蓋構夢鏇齋窪 積醖醖觸顧顧願顧網繭 (壓構鑰襯窪繭顧襯鬱觸 ) 更多 | ||||||
N/A | 18 | 襯鑰遞齋遞鏇壓壓範鏇(蓋鬱壓鏇鏇構構遞艱窪) = 鹽蓋鬱糧蓋憲遞簾構選 獵積齋襯膚鹽鹽積衊襯 (製顧簾鹽廠選齋壓構願 ) 更多 | 积极 | 2026-03-22 | |||
(patients achieving complete remission prior to ASCT) | 襯鑰遞齋遞鏇壓壓範鏇(艱艱廠遞鹽獵願繭齋簾) = 糧積餘鑰齋廠網選鹹蓋 鹹願簾淵鬱鬱觸憲蓋廠 (糧窪窪築簾觸築艱鏇網 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用